Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis
Abstract Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initia...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-023-01596-4 |
| _version_ | 1797363500502220800 |
|---|---|
| author | Kateřina Klíčová Jan Mareš Kateřina Menšíková Michaela Kaiserová David Friedecký Petr Kaňovský Miroslav Strnad Radoslav Matěj |
| author_facet | Kateřina Klíčová Jan Mareš Kateřina Menšíková Michaela Kaiserová David Friedecký Petr Kaňovský Miroslav Strnad Radoslav Matěj |
| author_sort | Kateřina Klíčová |
| collection | DOAJ |
| description | Abstract Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initial symptoms. Our study focused on cerebrospinal fluid (CSF) concentrations of clusterin, tau protein, phosphorylated tau protein, and beta-amyloid1–42 in ALS patients and a control group. Methods Our study involved 54 ALS patients and 58 control subjects. Among the ALS patients, 14 presented with bulbar-onset ALS, and 40 with limb-onset ALS. We quantified biomarker levels using enzyme-linked immunosorbent assay (ELISA) and compared the results using the Mann–Whitney U-test. Results Significant elevations in neurodegenerative markers, including tau protein (p < 0.0001), phosphorylated tau protein (p < 0.0001), and clusterin (p = 0.038), were observed in ALS patients compared to controls. Elevated levels of tau protein and phosphorylated tau protein were also noted in both bulbar and limb-onset ALS patients. However, no significant difference was observed for beta-amyloid1–42. ROC analysis identified tau protein (AUC = 0.767) and p-tau protein (AUC = 0.719) as statistically significant predictors for ALS. Conclusion Our study demonstrates that neurodegenerative marker levels indicate an ongoing neurodegenerative process in ALS. Nonetheless, the progression of ALS cannot be predicted solely based on these markers. The discovery of a specific biomarker could potentially complement existing diagnostic criteria for ALS. |
| first_indexed | 2024-03-08T16:22:15Z |
| format | Article |
| id | doaj.art-444665e8162f412fbde059b5b1e3737a |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-03-08T16:22:15Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-444665e8162f412fbde059b5b1e3737a2024-01-07T12:17:32ZengBMCEuropean Journal of Medical Research2047-783X2024-01-012911910.1186/s40001-023-01596-4Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosisKateřina Klíčová0Jan Mareš1Kateřina Menšíková2Michaela Kaiserová3David Friedecký4Petr Kaňovský5Miroslav Strnad6Radoslav Matěj7Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital OlomoucDepartment of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital OlomoucDepartment of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital OlomoucDepartment of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital OlomoucLaboratory of Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacky University and University Hospital OlomoucDepartment of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital OlomoucDepartment of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital OlomoucDepartment of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer University HospitalAbstract Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initial symptoms. Our study focused on cerebrospinal fluid (CSF) concentrations of clusterin, tau protein, phosphorylated tau protein, and beta-amyloid1–42 in ALS patients and a control group. Methods Our study involved 54 ALS patients and 58 control subjects. Among the ALS patients, 14 presented with bulbar-onset ALS, and 40 with limb-onset ALS. We quantified biomarker levels using enzyme-linked immunosorbent assay (ELISA) and compared the results using the Mann–Whitney U-test. Results Significant elevations in neurodegenerative markers, including tau protein (p < 0.0001), phosphorylated tau protein (p < 0.0001), and clusterin (p = 0.038), were observed in ALS patients compared to controls. Elevated levels of tau protein and phosphorylated tau protein were also noted in both bulbar and limb-onset ALS patients. However, no significant difference was observed for beta-amyloid1–42. ROC analysis identified tau protein (AUC = 0.767) and p-tau protein (AUC = 0.719) as statistically significant predictors for ALS. Conclusion Our study demonstrates that neurodegenerative marker levels indicate an ongoing neurodegenerative process in ALS. Nonetheless, the progression of ALS cannot be predicted solely based on these markers. The discovery of a specific biomarker could potentially complement existing diagnostic criteria for ALS.https://doi.org/10.1186/s40001-023-01596-4Amyotrophic lateral sclerosisCerebrospinal fluidBiomarkers |
| spellingShingle | Kateřina Klíčová Jan Mareš Kateřina Menšíková Michaela Kaiserová David Friedecký Petr Kaňovský Miroslav Strnad Radoslav Matěj Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis European Journal of Medical Research Amyotrophic lateral sclerosis Cerebrospinal fluid Biomarkers |
| title | Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis |
| title_full | Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis |
| title_fullStr | Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis |
| title_full_unstemmed | Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis |
| title_short | Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis |
| title_sort | utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis |
| topic | Amyotrophic lateral sclerosis Cerebrospinal fluid Biomarkers |
| url | https://doi.org/10.1186/s40001-023-01596-4 |
| work_keys_str_mv | AT katerinaklicova utilizingneurodegenerativemarkersforthediagnosticevaluationofamyotrophiclateralsclerosis AT janmares utilizingneurodegenerativemarkersforthediagnosticevaluationofamyotrophiclateralsclerosis AT katerinamensikova utilizingneurodegenerativemarkersforthediagnosticevaluationofamyotrophiclateralsclerosis AT michaelakaiserova utilizingneurodegenerativemarkersforthediagnosticevaluationofamyotrophiclateralsclerosis AT davidfriedecky utilizingneurodegenerativemarkersforthediagnosticevaluationofamyotrophiclateralsclerosis AT petrkanovsky utilizingneurodegenerativemarkersforthediagnosticevaluationofamyotrophiclateralsclerosis AT miroslavstrnad utilizingneurodegenerativemarkersforthediagnosticevaluationofamyotrophiclateralsclerosis AT radoslavmatej utilizingneurodegenerativemarkersforthediagnosticevaluationofamyotrophiclateralsclerosis |